S&P 500
(0.12%) 5 303.27 points

Dow Jones
(0.34%) 40 004 points

Nasdaq
(-0.07%) 16 686 points

Oil
(0.04%) $80.09

Gas
(1.83%) $2.67

Gold
(0.96%) $2 440.60

Silver
(3.68%) $32.41

Platinum
(0.92%) $1 100.00

USD/EUR
(-0.08%) $0.919

USD/NOK
(-0.12%) $10.66

USD/GBP
(-0.02%) $0.787

USD/RUB
(0.09%) $91.05

Realtime updates for Zydus Lifesciences [CADILAHC.NS]

Exchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Last Updated31 Dec 1970 @ 19:00

25% discount on Stockinvest.us - Use code: Podcast

0.03% INR 346.05

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally...

Stats
Today's Volume	856 777
Average Volume	2.11M
Market Cap	0.00
EPS	INR4.77 ( 2021-12-30 )
Last Dividend	INR3.50 ( 2021-07-29 )
Next Dividend	INR0 ( N/A )
P/E	7.43
ATR14	INR0 (0.00%)

Zydus Lifesciences Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zydus Lifesciences Financials

Annual	2022
Revenue:	INR170.51B
Gross Profit:	INR68.01B (39.89 %)
EPS:	INR19.30

FY	2022
Revenue:	INR170.51B
Gross Profit:	INR68.01B (39.89 %)
EPS:	INR19.30

FY	2021
Revenue:	INR148.22B
Gross Profit:	INR93.42B (63.03 %)
EPS:	INR20.84

FY	2020
Revenue:	INR138.12B
Gross Profit:	INR86.63B (62.72 %)
EPS:	INR11.49

Financial Reports:

No articles found.

Zydus Lifesciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Zydus Lifesciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.12 - low (37.09%) | Divividend Growth Potential Score: 3.01 - No dividend growth expected in the near future

Information

First Dividend	INR0.200	2000-05-02
Last Dividend	INR3.50	2021-07-29
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR96.45	--
Avg. Dividend % Per Year	0.19%	--
Score	1.87	--
Div. Sustainability Score	4.12
Div.Growth Potential Score	3.01
Div. Directional Score	3.57	--

Next Divdend (Est)
(2024-07-09)

INR0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.87

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.50	0.90%
2019	INR3.50	1.00%
2020	INR3.50	1.38%
2021	INR3.50	0.73%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NLCINDIA.NS	Dividend Knight	2023-09-18	Annually	25	3.45%
INDIAGLYCO.NS	Dividend Junior	2023-09-05	Sporadic	20	0.85%
CHAMBLFERT.NS	Dividend Knight	2023-08-21	Annually	23	1.58%
SATINDLTD.NS	Dividend Knight	2023-07-11	Semi-Annually	2	0.10%
MAGADSUGAR.NS	Dividend Knight	2023-07-13	Annually	7	1.78%
GICRE.NS	Dividend Junior	2023-09-07	Sporadic	7	1.34%
ARVSMART.NS	Dividend Junior	2023-07-21	Sporadic	6	0.13%
TOUCHWOOD.NS	Dividend Junior	2023-09-22	Annually	6	0.15%
PFC.NS	Dividend King	2023-06-16	Quarterly	18	7.12%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.156	1.500	6.87	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.328	1.500	7.46	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	57.27	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	14.57	2.00	5.14	10.00	[0 - 30]
freeCashFlowPerShareTTM	14.57	2.00	2.71	5.43	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.470	1.000	5.49	5.49	[0.2 - 0.8]
operatingProfitMarginTTM	0.224	1.000	7.53	7.53	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.78	1.000	8.91	0	[1 - 100]
returnOnEquityTTM	0.328	2.50	8.37	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	14.57	2.00	5.14	5.43	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	14.57	2.00	5.14	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.324	1.500	-5.49	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0775	1.000	-0.562	0	[0.1 - 0.5]
Total Score				3.01

Zydus Lifesciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.